The Monrovia, Calif.-based company said that with the approval, its ICL product line is now cleared for the correction of refractive errors in patients with both myopia and astigmatism.
Staar Surgical said that its ICLs in both spherical and toric designs have been associated with “significant improvements in quality of life,” and touted that patients who’ve received ICL surgery as “life changing,” according to a press release.
“FDA’s approval of Staar’s Visian toric ICL in the U.S. provides an exciting treatment option for myopic patients with astigmatism in search of visual freedom. We are thrilled to be able to offer this lens in the United States and look forward to officially making the Visian toric ICL available to U.S. surgeons for their patients on November 1st, 2018,” prez & CEO Caren Mason said in a prepared statement.
Last month, Staar Surgical priced an offering of shares looking to raise up to $67.8 million with proceeds slated to support commercialization of its collamer lens products and other activities.